

Innovation in Drug Discovery/Development and Alliances

Kenji Nishimura and ○Junichi Ryokai
(JPMA R&D Committee (Sankyo Co., Ltd.))

Academia(A), Regulatory/Government(R) and Industry(I) cooperation is necessary for an innovative new drug to reach patients. In a typical drug discovery and development, a drug candidate transferred from A to I clears the narrow path of lead optimizing and most complicated pre-clinical phase to enter the A-medical and I joint study in clinical trials.

Good scientific advice by R on the design and protocols of clinical trials including the endpoints of the trials opens the way to further development of the drug. The process of an appropriate review by R of technical document submitted in the form of NDA depends on good and accountable RI alliance.

Current major issues to be discussed in the arena are as follows:

- ✧ The feature and contribution of government funding in drug discovery and development
- ✧ Perspectives of government basic research to seek newer drug candidates and importance of ARI alliance
- ✧ Accomplishments and problems of ARI joint project supported by JPMA(Japan Pharmaceutical Manufacturers Association)
- ✧ Dialogs between R and I from the earlier phase of drug discovery and development make innovation easier
- ✧ Understanding by public of innovative R&D to generate innovative drugs needed to improve health care would enhance more timely and cost-effective drug launch